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We report microsecond timescale ligand ﬁeld molecular dynamics simulations of the copper complexes of three
known mutants of the amyloid-β peptide, E22G, E22Q and E22K, alongside the naturally occurring sequence. We
ﬁnd that all three mutants lead to formation of less compact structures than the wild-type: E22Q is the most
similar to the native peptide, while E22G and especially E22K are markedly different in size, shape and stability.
Turn and coil structures dominate all structures studied but subtle differences in helical and β-sheet distribution
are noted, especially in the C-terminal region. The origin of these changes is traced to disruption of key salt
bridges: in particular, the Asp23-Lys28 bridge that is prevalent in the wild-type is absent in E22G and E22K, while
Lys22 in the latter mutant forms a strong association with Asp23. We surmise that the drastically different pattern
of salt bridges in the mutants lead to adoption of a different structural ensemble of the peptide backbone, and
speculate that this might affect the ability of the mutant peptides to aggregate in the same manner as known for
the wild-type.1. Introduction
Alzheimer's disease (AD) is characterised by the deposition of
abnormal structures in the brain, particularly plaques – consisting of the
Amyloid-β (Aβ) peptide – and neuroﬁbrillary tangles. Aβ has two common
isoforms, 40 and 42 residues in length, and is generated by sequential
cleavage of the amyloid precursor protein (APP) by β- and γ-secretases.
There are around ﬁfteen known mutations of Aβ that may affect its
structure and properties, and hence neurobiology. Formation of ﬁbrils,
probed by ThT ﬂuorescence assays, was thought to be the key event in AD
[1, 2], but more recent evidence suggests that small soluble Aβ oligomers
are the key toxic species in the disease [3, 4]. Interestingly, more clinically
severe mutations are associated with less ThT-responsive features [5]. In
addition, Aβ variations at positions Ala21-Asp23 produce less ThT
response over time than wild-type Aβ, despite forming aggregates [6].
Indeed, these mutants possess high aggregation rates [7], in agreement
with the idea that non-ThT-responsive structures are involved in the AD
process, while those that provide a ThT response are not necessarily
pathogenic [8, 9, 10]. This is supported by data from a series of Glu22
(E22) mutants, which display accelerated formation of Aβ intermediates,
increased neurotoxicity, but reduced ﬁbril formation [7, 11]..
m 25 November 2019; Accepted
vier Ltd. This is an open access aThe role of metal ions in AD is increasingly recognised, as disease
progression correlates with the breakdown in homeostasis of copper, iron
and zinc in the brain [12, 13, 14, 15, 16]. These ions play a key role in
both the formation of aggregates and their neurotoxicity; concentrations
of Cu(II) and Zn(II) are elevated in plaques of AD brains [17, 18], while
plaques without these metals have been found to be non-toxic [19].
Furthermore, the redox activity of Cu(II) in particular provides a mech-
anism for damage to brain tissue via generation of reactive oxygen spe-
cies (ROS) [20, 21]. The exact role and nature of these metal ions in AD is
a subject of growing research interest, and has been extensively reviewed
elsewhere [12, 13, 22, 23, 24]. Metal ion coordination has important
effects on the structure and properties of Aβ, including aggregation
propensity, though the recorded effects are diverse [13, 25]. In general,
metal ions induce Aβ aggregation [26, 27, 28] though the type and
toxicity of aggregate formed varies [29, 30, 31].
Cu(II) possesses high afﬁnity towards Aβ [12, 32, 33] and dominates
its coordination chemistry. A range of experimental and simulation
studies have established details of Cu(II) coordination: the N-terminal
region of the peptide contains the metal binding sites, though the exact
nature of the coordinating residues depends on pH [34, 35, 36, 37, 38,
39]. Typically, Cu(II) binds through three N-donors and one O-donor, via13 December 2019
rticle under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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ﬁbril formation, instead forming non-ﬁbrillar aggregates and converting
β-strand peptide structure into helices [39, 40]. The aetiology of disease
onset is complex and not fully understood, but relative concentrations of
metal and peptide can induce changes in the size and shape of aggregates
formed [29, 32].
To date there have been very few studies of the effect of metal co-
ordination on the structure, interactions or chemistry of Aβ mutants. InFigure 1. RMSD (Å) from initial structure of each trajectory,
2this work, molecular dynamics simulations were carried out on Cu(II)
complexes with three E22 mutants, namely E22G, E22Q, and E22K, and
compared to previous studies of the wild-type (WT) [41]. All are known
mutants with established effects on aggregation and neurotoxicity.
Moreover, they span a range of physico-chemical properties, from the
anionic side chain in WT, through a polar but uncharged residue (E22Q)
and small, uncharged amino acids (E22G), to a positively charged residue
(E22K).against time (μs): a) E22G, b) E22Q, c) E22K and d) WT.
Table 1. RMSD (Å) of E22 mutants.
avg RMSD SD max min
E22G-1 2.28 0.57 0.42 5.29
E22G-2 4.73 1.08 1.11 6.72
E22G-3 5.41 1.13 1.14 8.48
E22Q-1 4.89 0.70 1.34 8.12
E22Q-2 1.22 0.19 0.60 2.15
E22Q-3 2.44 0.35 0.81 4.21
E22K-1 5.88 0.44 0.95 7.29
E22K-2 2.77 0.66 0.79 5.07
E22K-3 3.89 0.60 1.27 6.70
WT-1 16.39 0.58 17.56 14.98
WT-2 6.77 0.23 7.93 5.78
WT-3 4.92 0.13 5.40 4.42
Table 2. Radius of gyration (Å) of E22 mutants.
avg Rg SD max min
E22G 21.59 1.46 24.28 15.88
E22Q 15.81 3.75 23.68 10.59
E22K 18.95 3.02 23.73 14.08
WT 13.78 5.53 22.83 8.82
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Wildtype Aβ1-42 was constructed within MOE [42] and Cu(II) was
coordinated in the [OcA2,NεH6,NδH13,NεH14] binding mode. Mutations were
made using MOE's inbuilt sequence editor to generate the three E22
mutants. Residue protonation states were assigned to those appropriate
for physiological pH values. Low mode molecular dynamics [43] simu-
lations were carried out in the DommiMOE extension [44] to MOE, uti-
lising previously reported Cu(II) ligand ﬁeld molecular mechanics
(LFMM) parameters [45] and AMBER PARM94 [46] parameters for all
other atoms, to generate a diverse library of starting structures for further
simulations. In particular, a combination of LFMM parameters from TypeTable 3. Hydrogen bond count for E22 mutants.
avg H-bond # SD max min
E22G 8.46 2.26 18 0
E22Q 10.31 2.58 22 1
E22K 8.80 2.86 22 0
WT 9.90 2.63 25 1
Figure 2. Root mean square ﬂuctuation (Å) of E22 mutants.
3I copper protein with Cu–N bonding terms optimised for model Cu/i-
midazole/formamide complexes successfully reproduces DFT structures.
Partial charge assignment was carried out using MOE's dictionary lookup
feature and then copper and coordination sphere charges modiﬁed as
reported previously [45]. We note that other binding modes are known,
but our goal here is to compare mutants with a common coordination to
copper, not to explore all available binding sites. The functional form of
the LFMM implementation of AMBER, in which M—L bonds are
described with a Morse potential, means that metal-ligand dissociation is
effectively impossible, at least at the temperatures and over the time-
scales used here.
Ligand ﬁeld molecular dynamics (LFMD) simulations were carried
out using the DL_POLY_LF code [47], which incorporates LFMM within
the DL_POLY_2.0 package [48]. All simulations were carried out using an
NVT ensemble, with a Nose-Hoover thermostat with relaxation constant
of 0.5 ps, at a temperature of 310 K. Implicit solvation was modelled
through the reaction ﬁeld model with dielectric suitable for bulk water (ε
¼ 80) with cutoffs of 10 and 21 Å, for van der Waals interactions and long
range electrostatics, respectively. Use of implicit solvent has been shown
to enhance conformational sampling of ﬂexible systems [49]. All bonds
to hydrogen were constrained using the SHAKE algorithm [50], with
108 Å tolerance. All simulations were run for 1 μs, with a 1 fs integration
timestep used throughout. Atomic positions were recorded every 10 ps
for trajectory analysis.
All analysis of LFMD trajectories was carried out using VMD 1.9.2
[51]. Root mean square deviation (RMSD) and radius of gyration (Rg)
were used as indicators of equilibration. The VMD timeline extension was
used for secondary structure, root mean square ﬂuctuations (RMSF), salt
bridge, and hydrogen bond analysis. Tertiary structure Cα contact maps
were created using the ITrajComp plugin [52]. Hydrogen bond presence
was determined by a distance of less than 3 Å and angle of less than 20
between donor and acceptor. Salt bridge presence was determined by less
than 3.2 Å between O and N atoms on charged residues: this deﬁnition
means that it is possible for a residue to form multiple simultaneous salt
bridges, so the total percentages for any given residue may exceed 100%.
2. Results and discussion
Three low energy structures generated by low mode molecular dy-
namics, with mutual RMSD greater than 1.5 Å, were chosen as separate
starting points for LFMD simulations, to allow for more effective sam-
pling of conformational phase space. Microsecond LFMD simulations
were carried out for each of the three starting points, for each mutant,
and associated RMSD plots are reported in Figure 1. The intrinsically
disordered Aβ peptide offers complications when equilibrating MD sim-
ulations. As such, full equilibration would only occur on timescales
beyond current computational capabilities. Therefore we have utilised
the description of quasi-equilibration, as reported by Huy et al. [53],
where RMSD ﬂuctuation around a stable point is sufﬁcient to consider a
simulation equilibrated.
For our systems, timescales in the order of hundreds of nanoseconds
are required: quasi-equilibration for E22G required 200, 200, and 500 ns
of simulation; E22Q required 250, 250, and 300 ns; E22K required 300,
500, and 500 ns; while WT required 200, 300, and 100 ns for runs 1–3
respectively. Table 1 reports statistics drawn from RMSD values for the
quasi-equilibrated portion of each trajectory. All three simulations for all
three mutants result in low standard deviation values, showing that
beyond the equilibration point the trajectories are generally stable.
Rg values for individual trajectories show stable values past the
equilibration times noted above: Table 2 reports values averaged over all
post-equilibration trajectories. High standard deviation values are a
result of the combination of multiple trajectories: variation is much
smaller within trajectories. WT has the lowest average Rg, indicating the
most compact structure: the mean value compares well with literature
[54]. Ref 54 reports Rg of Aβ1-42 in the range 9–13 Å, with a mean of
1.14 nm, while values of 10–15 Å are quoted in ref [55]. E22Q is only
Figure 3. Residue contact maps, based on Cα distances (Å): a) E22G, b) E22Q, c) E22K, d) WT.
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However, mutation to the small, achiral glycine (E22G) or the positively
charged lysine (E22K) result in the most obvious differences in
compactness of structure, with average values increased by almost 8 and
over 5 Å, respectively.
Data relating to the hydrogen bonding within mutants is reported in
Table 3. As with our previous study on WT, hydrogen bonds in all mu-
tants considered are highly transient. High standard deviation values
relative to the average number of H-bonds, along with minimum
numbers as low as zero and maximum numbers as high as 25, are
indicative of transience. Common H-bonds, reported as donor-acceptor,
include Asn27 backbone-Asp23 backbone (42% incidence) and Gln15
sidechain-Glu11 sidechain (38%) for WT; His14 backbone-Asp7 side-
chain (31%) and Ser26 sidechain-Asp23 sidechain (24%) for E22G; Ser26
sidechain-Asp23 sidechain (44%) and His14 sidechain-Glu11 sidechain
(38%) for E22Q; and Ser8 sidechain-Asp7 sidechain (40%) and Asn27
backbone-Ala42 backbone (21%) for E22K. Several H-bonds ﬁtting the
expected iþ4 → i pattern for α-helices are observed, including N27-D23
in WT, consistent with secondary structure patterns discussed below.
Figure 2 shows the RMSF of the mutants by residue, compared to the
wildtype. WT exhibits the lowest RMSF for all residues compared to the
mutated peptides. Interestingly, the mutated residues are not necessarily
those with largest RMSF values; this is somewhat surprising due to the4different chemical nature of the residues involved. Figure 2 indicating
that the effect of mutation on peptide ﬂexibility is highly non-local. In
general, the C-terminus exhibits larger RMSF values than the N-terminus,
as expected due to the anchoring effect of coordination of Cu(II) to three
N-terminal residues. However, E22K displays a different pattern: the N-
terminus has larger RMSF values than the C-terminus, with the coordi-
nating residues having relatively low values but many of the others in the
metal binding region exhibiting high mobility, notably Asp1-Phe4, Asp7-
Ser8 and Val12.
Contact maps are a useful measure of the average shapes of dynamical
systems and have been utilised to compare the different mutants here.
Figure 3 reports contact maps between the α-carbons of each residue for
the mutants and the wildtype. WT has a relatively compact structure,
with longest Cα-Cα distances of ca. 30 Å between Ser8-Phe20 and Lys28-
Val40. E22Q shows a more extended structure: distances of ca. 40 Å for
N-terminal residues (up to Gly9) with C-terminal residues Ile32-Gly38.
Mutation to the oppositely charged lysine (E22K) results in a strikingly
different contact map, with much greater separation between the
termini, corresponding to an extended structure. This is observed to an
even greater extent in the E22G mutation, wherein Cα-Cα contacts be-
tween the termini exceed 50 Å for residues up to Gln15 with Il32-Val40.
Structures of ﬁnal the ﬁnal frames of MD trajectories are also reported in
Figure 4, which are in agreement with the ﬁndings for the contact maps.
Figure 4. Final frames of LFMD trajectories for a) E22G, b) E22Q, c) E22K, d) WT.
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rithm: percentage secondary structure against residue number is reported
in Figure 5. A breakdown of the overall contributions of secondary
structure elements for each mutation is also reported in Table 4. As ex-
pected for intrinsically disordered peptides, the major constituents of theFigure 5. Percentage secondary structure of E22 mutants. C, I, G, H, B, E, and T, corre
and turn, respectively: a) E22G, b) E22Q, c) E22K, d) WT.
5secondary structure proﬁle are turn and coil. These structural elements
correspond to a lack of order and comprise over 70% of the total peptide
structure for all systems. Interestingly, there is considerable variation in
helix and sheet content between the mutants. All systems have very little
β-sheet character: the largest being 2.3% for E22Q, found in the in thespond to the structure elements coil, π-helix, 310 helix, α-helix, β-bridge, β-sheet,
Table 4. Breakdown of percentage secondary structure for E22 mutants.
Helix % Sheet % Turn/Coil %
E22G 15.4 1.6 83.1
E22Q 25.2 2.3 72.5
E22K 25.3 0.8 73.9
WT 18.6 0.4 81.0
S.T. Mutter et al. Heliyon 6 (2020) e03071metal binding region as well as the peptide's central hydrophobic core
(Leu17-Ala21). In contrast, the WT peptide adopts sheet-like conforma-
tions exclusively at the C-terminus.
There are also differences in helical content across the mutants, 25%
in E22K compared to 19% in WT. These consist of a mix of π, 310 and,
α-helices: the latter twomaking up the majority. These are primarily seen
in the regions of Tyr10-Gln15 and Gly25-Val40 residues. WT and E22G,
but not E22Q nor E22K, exhibit π helices in the metal binding region site
near His13 and His14. Some π-helical character is also observed toward
the C terminus in some mutants but at much lower occurrences. AFigure 6. Ramachandran plots of a)
6distinction can also be made between turn and coil structures: the mu-
tants that result in the most extended structures, E22G and E22K, have
the greatest concentration of coil structure. This character is centred on
the central hydrophobic region and toward the C terminus. The coil
character therefore indicates this presence, whilst E22Q and WT in-
dicates a greater propensity to remain globular.
Ramachandran maps (Figure 6) shed further light on secondary
structure: for WT Aβ, most conformations adopt right-handed helical-like
conformations, centred around (-60, -20). Interestingly, there are many
further conformations located around (-135, -15), close to the helical
region of the plot. In addition, there are notable contributions from left-
handed helical structures at (45, -15) and β-sheet type structures at (-160,
160). E22K and E22Q mutants exhibit similar Ramachandran maps,
dominated by right-handed helical-like conformations, indicating that
these mutations have relatively little effect on the total backbone con-
formations sampled. This reﬂects their similar secondary structure pro-
ﬁles. E22Q reports the highest incidence of β-sheet structure, but has
relatively few conformations in this region of the plot, indicating thatE22G, b) E22Q, c) E22K, d) WT.
Figure 7. Percentage occurrence of salt bridges for a) E22G, b) E22Q, c) E22K, d) WT.
Figure 8. Asp23-Lys28 salt bridge distribution (Å) against percent
of occurrence.
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7while mutants adopt sheet-like conformations, they lack the requisite
hydrogen bonds to be classiﬁed as β-sheets. E22G is also dominated by
helical-type conformations, but also contains more β-sheet structures.
This is in agreement with other data illustrated here; this mutation ex-
hibits the second-highest degree of β-sheet structure, as well as the most
extended conformation.
Salt bridge interactions strongly inﬂuence peptide structure and sta-
bility. The natural peptide has nine charged residues at physiological pH,
three positive and six negative, resulting in a possible eighteen salt
bridges: E22Q and E22G have ﬁfteen possible bridges, and E22K twenty.
Salt bridge contact maps for each structure are reported in Figure 7. All
systems show similarities in the metal binding region, which may be
expected due to their identical copper bindingmodes. The Asp1-Arg5 salt
bridge is present at close to 100% of the time for all mutants, but just 63%
for WT. WT contains an Asp1-Lys28 salt bridge (27%), which is not
present in the mutants, reﬂecting the more compact structure of the WT
compared to the mutants (vide supra). Other differences in this region
include the presence of Glu3-Arg5 interactions in E22G, which are not
observed for the other systems. Lys22 in E22K forms new salt bridge
interactions, particularly with Glu11 (29%) and Asp23 (100%): these
new interactions are formed at the expense of those with Lys28, observed
in other mutants. Reduction of the stabilising interactions of Lys28 with
the closer Lys22 therefore seems to be the likely origin of the extended
conformation observed from the contact maps above.
The Asp23-Lys28 bridge plays an important role in the aggregation
behaviour of Aβ [56]: mutation of a residue directly adjacent seems likely
to have an impact. To examine this inﬂuence, the Asp23-Lys28 distance
has been plotted for the mutants and WT in Figure 8. WT exhibits a sharp
peak at 3.5 Å, and a much shallower, broad peak above 20 Å, illustrating
the presence of two conformations. A similar proﬁle is observed for
E22Q, with the same sharp peak at 3.5 Å and smaller, broader peaks at
longer distances (12–14 Å). The twomutations that have no Asp23-Lys28
salt bridge interactions have no peaks below 5 Å E22G, the most
extended system, has a peak at ca. 25 Å, as well as two at 8 and 13 Å,
S.T. Mutter et al. Heliyon 6 (2020) e03071while E22K lacks the peak at very long distance but exhibits peaks around
8, 15, and 17 Å.
3. Conclusions
We report ligand ﬁeld molecular dynamics simulations of the Cu(II)
complexes formed by three different Glu22 mutants of the amyloid-β
1–42 peptide: namely E22G, E22Q and E22K. All are known to increase
the rate of peptide aggregation and the likelihood of developing the
symptoms of Alzheimer's disease. Three independent simulations of one
microsecond for each system were performed, each reaching pseudo-
equilibration after several hundred nanoseconds. Analysis of frames
collected after equilibration indicates major differences betweenmutants
and the wild-type peptide. E22Q is the most similar to the native peptide,
but even here subtle differences are evident. E22G and especially E22K
are markedly different in size, shape and stability, both adopting much
more extended structures that are much more ﬂexible. Somewhat sur-
prisingly, changes induced by mutations are apparent across the entire
peptide: root mean square ﬂuctuation in particular shows that E22K in-
duces major changes in the N-terminal sequence, up to 20 residues away
from the site of mutation, while E22G causes the C-terminus to become
much more ﬂexible. In common with a previous MD study of mutated Aβ
[57], turn and coil structures dominate all structures studied but subtle
differences in helical and β-sheet distribution are noted, especially in the
C-terminal region. All mutants, as well as WT, sample a wide set of
structural ensembles: this structural diversity and the conformational
may facilitate the interconversions between various secondary and ter-
tiary structures that accompany aggregation of Aβ.
The origin of these difference is apparently disruption to the salt-
bridge network: E22Q has a strongly populated Arg5-Asp7 interaction
that is absent in WT, while the Glu11-Lys16 bridge that is frequently
populated in WT is much reduced. E22K leads to a quite different pattern
of salt bridges, with the mutated residue itself forming interactions with
Glu11 and especially Asp23. E22G leads to complete loss of the Asp1-
Lys28 interaction and diminution of Glu11-Lys18. Both mutations
therefore leads to substantial reduction in the interactions that keep the
wild-type peptide in a relatively compact conformation, and hence to the
extended conformations noted above. While we cannot draw direct
conclusions on the effect of mutation on aggregation from these simu-
lation of monomers, it is intriguing that the E22G and E22K are known to
give rise to “small protoﬁbrils and oligomers” and to “less ﬁbrillar” ag-
gregates, respectively [58]. We speculate that the loss of salt bridges
within the monomer and the resulting extended structure give rise to
different aggregation behaviour, and that the characteristic fold of Aβ
seen in mature ﬁbrils may be less favourable in the absence of key salt
bridges such as Asp23-Lys28.
It is appropriate at this stage to discuss limitations of this work.
Firstly, we have only studied 1:1 Cu:peptide complexes, and then only in
one of several possible coordination modes. This may not be represen-
tative of the more complex in vivo situation, but serves as a basis for
comparison of mutants without further complication of changing stoi-
chiometry or coordination. Secondly, we have also only simulated
monomeric Aβ whereas oligomers are thought to be the key species in
disease onset: we hope to report simulations of larger systems in future
publications, but at present we can only infer potential interactions from
the properties of the monomer. Thirdly, use of an implicit solvent model
prevents the simulations from accounting for any explicit role of water
molecules in metal coordination. Despite these limitations, we have
identiﬁed important differences in the structure and dynamics of the
mutated peptides and their interaction with Cu(II) that give some insight
into how they behave in practice.
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